Receptor-binding domain-based subunit vaccines against MERS-CoV

Virus Research

Volumn 202, Issue , 2015, Pages 151-159

  Zhang, Naru ^a   Tang, Jian ^a   Lu, Lu ^b   Jiang, Shibo ^a,b   Du, Lanying ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

MERS CoV; Middle East respiratory syndrome coronavirus; Receptor binding domain; Subunit vaccines

Indexed keywords

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VIRUS VACCINE;

ARTICLE; CORONAVIRUS INFECTION; DRUG DEVELOPMENT; HUMAN; IMMUNE RESPONSE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; RECEPTOR BINDING DOMAIN; SARS CORONAVIRUS; VACCINATION; ANIMAL; CORONAVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; TRENDS; VIROLOGY;

ANIMALIA; CAMELIDAE; CORONAVIRUS;

ANIMALS; CORONAVIRUS INFECTIONS; DRUG DISCOVERY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84930033126     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.11.013     Document Type: Article

References (79)

1. Agnihothram S., Gopal R., Yount B.L., Donaldson E.F., Menachery V.D., Graham R.L., Scobey T.D., Gralinski L.E., Denison M.R., Zambon M., Baric R.S. Evaluation of serologic and antigenic relationships between Middle Eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J. Infect. Dis. 2014, 209(7):995-1006.
2. Almazán F., DeDiego M.L., Sola I., Zuñiga S., Nieto-Torres J.L., Marquez-Jurado S., Andrés G., Enjuanes L. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013, 4(5). e00650-00613.
3. Annan A., Baldwin H.J., Corman V.M., Klose S.M., Owusu M., Nkrumah E.E., Badu E.K., Anti P., Agbenyega O., Meyer B., Oppong S., Sarkodle Y.A., Kalko E.K., Lina P.H., Godlevska E.V., Reusken C., Seebens A., Gloza-Rausch F., Vallo P., Tschapka M., Drosten C., Drexler J.F. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg. Infect. Dis. 2013, 19(3):456.
4. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A., Alabdullatif Z.N., Assad M., Almulhim A., Makhdoom H., Madani H., Alhakeem R., Al-Tawfiq J.A., cotton M., Watson S.J., Kellam P., Zumla A.I., Memish Z.A. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 2013, 369(5):407-416. KSA MERS-CoV Investigation Team.
5. Azhar E.I., Hashem A.M., El-Kafrawy S.A., Sohrab S.S., Aburizaiza A.S., Farraj S.A., Hassan A.M., Al-Saeed M.S., Jamjoom G.A., Madani T.A. Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. MBio 2014, 5(4). e01450-01414.
6. Briese T., Mishra N., Jain K., Zalmout I.S., Jabado O.J., Karesh W.B., Daszak P., Mohammed O.B., Alagaili A.N., Lipkin W.I. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014, 5(3). e01146-01114.
7. Cao Z., Liu L., Du L., Zhang C., Jiang S., Li T., He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol. J. 2010, 7(1):299.
8. Chan J.F., Chan K.H., Choi G.K., To K.K., Tse H., Cai J.P., Yeung M.L., Cheng V.C., Chen H., Che X.Y., Lau S.K., Woo P.C., Yuen K.Y. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 2013, 207(11):1743-1752.
9. Chan J.F., Lau S.K., Woo P.C. The emerging novel Middle East respiratory syndrome coronavirus: the knowns and unknowns. J. Formos. Med. Assoc. 2013, 112(7):372-381.
10. Chen W.H., Du L., Chag S.M., Ma C., Tricoche N., Tao X., Seid C.A., Hudspeth E.M., Lustigman S., Tseng C.T., Bottazzi M.E., Hotez P.J., Zhan B., Jiang S. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum. Vaccin. Immunother. 2013, 10(3):648-658.
11. Chen Y., Rajashankar K.R., Yang Y., Agnihothram S.S., Liu C., Lin Y.L., Baric R.S., Li F. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 2013, 87(19):10777-10783.
12. Chu D.K., Poon L.L., Gomaa M.M., Shehata M.M., Perera R.A., Abu Zeid D., El Rifay A.S., Siu L.Y., Guan Y., Webby R.J., Ali M.A., Peiris M., Kayali G. MERS coronaviruses in dromedary camels, Egypt. Emerg. Infect. Dis. 2014, 20(6):1049-1053.
13. Coleman C.M., Liu Y.V., Mu H., Taylor J.K., Massare M., Flyer D.C., Glenn G.M., Smith G.E., Frieman M.B. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014, 32(26):3169-3174.
14. Coleman C.M., Matthews K.L., Goicochea L., Frieman M.B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. Gen. Virol. 2014, 95(Pt 2):408-412.
15. Cui J., Eden J.S., Holmes E.C., Wang L.F. Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus. Virol. J. 2013, 10(1):304.
16. de Wit E., Prescott J., Baseler L., Bushmaker T., Thomas T., Lackemeyer M.G., Martellaro C., Milne-Price S., Haddock E., Haagmans B.L., Feldmann H., Munster V.J. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PloS One 2013, 8(7):e69127.
17. de Wit E., Rasmussen A.L., Falzarano D., Bushmaker T., Feldmann F., Brining D.L., Fischer E.R., Martellaro C., Okumura A., Chang J., Scott D., Benecke A.G., Katze M.G., Feldmann H., Munster V.J. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. USA 2013, 110(41):16598-16603.
18. Devitt E. Lack of small animal model hinders MERS coronavirus research. Nat. Med. 2013, 19(8). 952-952.
19. Drosten C., Kellam P., Memish Z.A. Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 2014, 371(14):1359-1360.
20. Du L., He Y., Jiang S., Zheng B.J. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today 2008, 44(1):63-74.
21. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009, 7(3):226-236.
22. Du L., Kou Z., Ma C., Tao X., Wang L., Zhao G., Chen Y., Yu F., Tseng C.T., Zhou Y., Jiang S. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PloS One 2013, 8(12):e81587.
23. Du L., Ma C., Jiang S. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J. Infect. 2013, 67(4):348-350.
24. Du L., Zhang X., Zhou J., Chen M., He W., Zhang H.Y., Chan C.C., Poon V.K., Zhao G., Sun S., Cai L., Zhou Y., Zheng B.J., Jiang S. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PloS One 2011, 6(1):e16555.
25. Du L., Zhao G., Chan C., Sun S., Chen M., Liu Z., Guo H., He Y., Zhou Y., Zheng B.J., Jiang S. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009, 393(1):144-150.
26. Du L., Zhao G., Chan C.C., Li L., He Y., Zhou Y., Zheng B.J., Jiang S. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010, 23(2):211-219.
27. Du L., Zhao G., He Y., Guo Y., Zheng B.J., Jiang S., Zhou Y. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 2007, 25(15):2832-2838.
28. Du L., Zhao G., Kou Z., Ma C., Sun S., Poon V.K., Lu L., Wang L., Debnath A.K., Zheng B.J., Zhou Y., Jiang S. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 2013, 87(17):9939-9942.
29. Du L., Zhao G., Li L., He Y., Zhou Y., Zheng B.J., Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 2009, 384(4):486-490.
30. Du L., Zhao G., Sun S., Zhang X., Zhou X., Guo Y., Li Y., Zhou Y., Jiang S. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PloS One 2013, 8(1):e53568.
31. Du L., Zhao G., Yang Y., Qiu H., Wang L., Kou Z., Tao X., Yu H., Sun S., Tseng C.T. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J. Virol. 2014, 88(12):7045-7053.
32. Frey K.G., Redden C.L., Bishop-Lilly K.A., Johnson R., Hensley L.E., Raviprakash K., Luke T., Kochel T., Mokashi V.P., Defang G.N. Full-genome sequence of human betacoronavirus 2c Jordan-N3/2012 after serial passage in mammalian cells. Genome Announc. 2014, 2(3). e00324-00314.
33. Gao J., Lu G., Qi J., Li Y., Wu Y., Deng Y., Geng H., Li H., Wang Q., Xiao H., Tan W., Yan J., Gao G.F. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 2013, 87(24):13134-13140.
34. Haagmans B.L., Al Dhahiry S.H., Reusken C.B., Raj V.S., Galiano M., Myers R., Godeke G.-J., Jonges M., Farag E., Diab A., Ghobashy H., Alhajri F., Al-Thani M., Al-Marri S.A., Al Romaihi H.E., Al Khal A., Bermingham A., Osterhaus A.D., AlHajri M.M., Koopmans M.P. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 2014, 14(2):140-145.
35. Hansson M., Nygren P.A., Stahl S. Design and production of recombinant subunit vaccines. Biotechnol. Appl. Biochem. 2000, 32(2):95-107.
36. He Y., Li J., Li W., Lustigman S., Farzan M., Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 2006, 176(10):6085-6092.
37. He Y., Lu H., Siddiqui P., Zhou Y., Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 2005, 174(8):4908-4915.
38. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 2004, 324(2):773-781.
39. He Y., Zhu Q., Liu S., Zhou Y., Yang B., Li J., Jiang S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005, 334(1):74-82.
40. Hotez P.J., Bottazzi M.E., Tseng C.T., Zhan B., Lustigman S., Du L., Jiang S. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014, 16(7):529-531.
41. Hurst K.R., Ye R., Goebel S.J., Jayaraman P., Masters P.S. An interaction between the nucleocapsid protein and a component of the replicase-transcriptase complex is crucial for the infectivity of coronavirus genomic RNA. J. Virol. 2010, 84(19):10276-10288.
42. Ithete N.L., Stoffberg S., Corman V.M., Cottontail V.M., Richards L.R., Schoeman M.C., Drosten C., Drexler J.F., Preiser W. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg. Infect. Dis. 2013, 19(10):1697-1699.
43. Jiang S., Bottazzi M.E., Du L., Lustigman S., Tseng C.T., Curti E., Jones K., Zhan B., Hotez P.J. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev. Vaccines 2012, 11(12):1405-1413.
44. Jiang S., Lu L., Du L., Debnath A.K. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J. Infect. 2013, 66(5):464-466.
45. Jiang S., Lu L., Liu Q., Xu W., Du L. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg. Microbes Infect. 2012, 1(8):e13.
46. Li F., Li W., Farzan M., Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005, 309(5742):1864-1868.
47. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454.
48. Li Y., Du L., Qiu H., Zhao G., Wang L., Zhou Y., Jiang S., Gao J. A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses. Biosci. Trends 2013, 7(3):129-137.
49. Lu G., Hu Y., Wang Q., Qi J., Gao F., Li Y., Zhang Y., Zhang W., Yuan Y., Bao J., Zhang B., Shi Y., Yan J., Gao G.F. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013, 500(7461):227-231.
50. Lu L., Liu Q., Du L., Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 2013, 15(8):625-629.
51. Lu L., Liu Q., Zhu Y., Chan K.H., Qin L., Li Y., Wang Q., Chan J.F., Du L., Yu F., Ma C., Ye S., Yuen K.Y., Zhang R., Jiang S. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 2014, 5:3067.
52. Ma C., Li Y., Wang L., Zhao G., Tao X., Tseng C.T., Zhou Y., Du L., Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014, 32(18):2100-2108.
53. Ma C., Li Y., Wang L., Tao X., Zhang N., Yang Y., Tseng C.T., Li F., Zhou Y., Jiang S., Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design. Vaccine 2014, 32(46):6160-6176.
54. Memish Z.A., Cotten M., Meyer B., Watson S.J., Alsahafi A.J., Al Rabeeah A.A., Corman V.M., Sieberg A., Makhdoom H.Q., Assiri A., Al Masri M., Aldabbagh S., Bosch B.J., Beer M., Muller M.A., Kellam P., Drosten C. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 2014, 20(6):1012-1015.
55. Memish Z.A., Mishra N., Olival K.J., Fagbo S.F., Kapoor V., Epstein J.H., AlHakeem R., Durosinloun A., Al Asmari M., Islam A., Islam A., Kapoor A., Briese T., Daszak P., Al Rabeeah A.A., Lipkin W.I. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg. Infect. Dis. 2013, 19(11):1819-1823.
56. Memish Z.A., Zumla A.I., Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N. Engl. J. Med. 2013, 369(9):884-886.
57. Memish Z.A., Zumla A.I., Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.M. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 2013, 368(26):2487-2494.
58. Meyer B., Müller M.A., Corman V.M., Reusken C.B., Ritz D., Godeke G.J., Lattwein E., Kallies S., Siemens A., van Beek J., Drexler J.F., Muth D., Bosch B.J., Wernery U., Koopmans M.P., Wernery R., Drosten C. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg. Infect. Dis. 2014, 20(4):552-559.
59. Mou H., Raj V.S., van Kuppeveld F.J., Rottier P.J., Haagmans B.L., Bosch B.J. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 2013, 87(16):9379-9383.
60. Nowotny N., Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill. 2014, 19(16):20781.
61. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361(9366):1319-1325.
62. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Müller M.A., Dijkman R., Muth D., Demmers J.A., Zaki A., Fouchier R.A., Thiel V., Drosten C., Rottier P.J., Osterhaus A.D., Bosch B.J., Haagmans B.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495(7440):251-254.
63. Raj V.S., Smits S.L., Provacia L.B., van den Brand J.M., Wiersma L., Ouwendijk W.J., Bestebroer T.M., Spronken M.I., van Amerongen G., Rottier P.J., Fouchier R.A., Bosch B.J., Osterhaus A.D., Haagmans B.L. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 2014, 88(3):1834-1838.
64. Reusken C.B., Haagmans B.L., Müller M.A., Gutierrez C., Godeke G.J., Meyer B., Muth D., Raj V.S., Vries L.S., Corman V.M., Drexler J.F., Smits S.L., El Tahir Y.E., De Sousa R., van Beek J., Nowotny N., van Maanen K., Hidalgo-Hermoso E., Bosch B.J., Rottier P., Osterhaus A., Gortazar-Schmidt C., Drosten C., Koopmans M.P. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 2013, 13(10):859-866.
65. Scobey T., Yount B.L., Sims A.C., Donaldson E.F., Agnihothram S.S., Menachery V.D., Graham R.L., Swanstrom J., Bove P.F., Kim J.D., Grego S., Randell S.H., Baric R.S. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 2013, 110(40):16157-16162.
66. Sharmin R., Islam A.B. A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design. BMC Bioinform. 2014, 15(1):161.
67. Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., Osterhaus A.D., Haagmans B.L., Sutter G. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 2013, 87(21):11950-11954.
68. Tao X., Hill T.E., Morimoto C., Peters C.J., Ksiazek T.G., Tseng C.T. Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells. J. Virol. 2013, 87(17):9953-9958.
69. van Doremalen N., Miazgowicz K.L., Milne-Price S., Bushmaker T., Robertson S., Scott D., Kinne J., McLellan J.S., Zhu J., Munster V.J. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor dipeptidyl peptidase 4. J. Virol. 2014, 88(16):9220-9232.
70. Wang J., Tricoche N., Du L., Hunter M., Zhan B., Goud G., Didier E.S., Liu J., Lu L., Marx P.A., Jiang S., Lustigman S. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PloS One 2012, 7(5):e37019.
71. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., Guo D., Fu L., Cui Y., Liu X., Arledge K.C., Chen Y.H., Zhang L., Wang X. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013, 23(8):986-993.
72. Woo P.C., Lau S.K., Li K.S., Tsang A.K., Yuen K.Y. Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg. Microbes Infect. 2012, 1(11):e35.
73. Yang Y., Du L., Liu C., Wang L., Ma C., Tang J., Baric R.S., Jiang S., Li F. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc. Natl. Acad. Sci. USA 2014, 111(34):12516-12521.
74. Yao Y., Bao L., Deng W., Xu L., Li F., Lv Q., Yu P., Chen T., Xu Y., Zhu H., Yuan J., Gu S., Wei Q., Chen H., Yuen K.Y., Qin C. An animal model of MERS produced by infection of Rhesus Macaques with MERS coronavirus. J. Infect. Dis. 2014, 209(2):236-242.
75. Zakhartchouk A.N., Sharon C., Satkunarajah M., Auperin T., Viswanathan S., Mutwiri G., Petric M., See R.H., Brunham R.C., Finlay B.B., Cameron C., Kelvin D.J., Cochrane A., Rini J.M., Babiuk L.A. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 2007, 25(1):136-143.
76. Zaki A.M., Van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367(19):1814-1820.
77. Zhang N., Jiang S., Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 2014, 13(6):761-774.
78. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Zhao J., Gale M.J., Baric R.S., Enjuanes L., Gallagher T., McCray P.B., Perlman S. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA 2014, 111(13):4970-4975.
79. Zhu X., Liu Q., Du L., Lu L., Jiang S. Receptor-binding domain as a target for developing SARS vaccines. J. Thorac. Dis. 2013, 5(Suppl 2):S142-S148.